To a person 20 years ago, today’s medicine would seem like science fiction: routine DNA sequencing, gene editing, and surgery that can help an 80-year-old Mick Jagger dance. So what will the next two decades bring? We’ll peer into the mists, looking at advances in DNA sequencing, the state of the wearables revolution, and the potential of artificial intelligence to change the way drugs are discovered — and how medicine is practiced. We’ll also check into the financial apparatus that is supposed to fund all this cool research. Join us for a series of high-level, interactive sessions, and be part of the conversation.
ATTEND
Secure your virtual pass or apply now to join us in San Francisco
STAT Breakthrough Summits attract a wide range of attendees, including investors, top-level executives, entrepreneurs, up-and-coming leaders in science and R&D, as well as patients and patient advocates alike. Join us for an unparalleled opportunity to connect, learn, and drive innovation in health and medicine together.
Virtual Pass
$299
Unlock the live stream of the summit
Network on the virtual platform with fellow attendees
Browse the virtual conference floor
Access all programming recordings after the summit
New benefit
Get a free 1 year subscription to STAT+ with your purchase
STAT+ Subscribers save 25% off — check your inbox for your exclusive promo code
STAT is committed to making this summit accessible. Email us at [email protected] to inquire about academic, nonprofit, government, and patient discounts.
Speakers
Meet the speakers
Check back as we continue to add more speakers to the agenda! Learn more about how to apply to speak here.
Elisabeth Bik, MSc
Science Integrity Consultant
Peter Lee, Ph.D.
President, Microsoft Research
Andy Coravos
Managing Director, HumanFirst, acquired by ICON
Colin Murdoch
President of Isomorphic Labs & Chief Business Officer, Google DeepMind
Kimberly Powell
Vice President of Healthcare, NVIDIA
Sholto David, Ph.D.
Former Analytical Scientist
Ida Sim, M.D., Ph.D.
Professor and Chief Research Informatics Officer, UCSF
Gilad Almogy, Ph.D.
CEO and Co-Founder, Ultima Genomics
Sponsor Speaker
Jared Baeten, M.D., Ph.D.
Vice President, HIV Clinical Development, Gilead Sciences
Sponsor Speaker
Richard Bonneau, Ph.D.
VP Machine Learning for Drug Discovery, Genentech
Robert Blum
President & CEO, Cytokinetics
Sponsor Speaker
Patricia Brennan
Vice President of Science Technology, Chan Zuckerberg Initiative
Sponsor Speaker
Theofanis Karaletsos
Head of AI for Science, Chan Zuckerberg Initiative
Bob Kocher, M.D.
Partner, Venrock
Daphne Koller
CEO and Founder, insitro
Derek Lowe
Director, Discovery Sciences, Novartis; Author, “In the Pipeline”
Akira Matsuno
President, Chief Financial Officer, and Co-Founder, Tune
Vijay Pande, Ph.D.
General Partner, Andreessen Horowitz
Dina Radenkovic
CEO, Gameto
Shiv Rao, M.D.
CEO & Founder, Abridge
Mike Rea
CEO, IDEA Pharma
Kimberly Seals Allers
Founder, Irth App
Sponsor Speaker
Pierre Theodore, M.D.
Head, Patient Impact and Health Equity, Genentech
Moderator
Mario Aguilar
Health Tech Correspondent, STAT
Moderator
Rick Berke
Co-Founder and Executive Editor, STAT
Moderator
Allison DeAngelis
Biotech Startups and Venture Capital Reporter, STAT
Moderator
Adam Feuerstein
Senior Writer, Biotech, STAT
Moderator
Matthew Herper
Senior Writer, Medicine; Editorial Director of Events, STAT
Moderator
Lizzy Lawrence
Medical Devices Reporter, STAT
Moderator
Katie Palmer
Health Tech Correspondent, STAT
Moderator
Casey Ross
National Health Technology Correspondent, STAT
Moderator
Nicholas St. Fleur
General Assignment Reporter; Associate Editorial Director of Events, STAT
Moderator
Jonathan Wosen, Ph.D.
West Coast Biotech & Life Sciences Reporter, STAT
AGENDA
Join us in San Francisco or virtually
Full agenda and timing will be listed 3-4 weeks before the event. All times listed in PDT.
Peter Lee, Ph.D., president, Microsoft Research
Katie Palmer, health tech correspondent, STAT (moderator)
Microsoft has emerged as a leading player in generative AI, including in health care. The first big foray is in note-taking. But how else could large language models help doctors do their jobs?
9:20 a.m.
Demo: To Be Announced
10 min
9:30 a.m.
NVIDIA Takes On One of the World’s Biggest Challenges: Inventing Drugs
20 min
Kimberly Powell, vice president of Healthcare, NVIDIA
Casey Ross, national health technology correspondent, STAT (moderator)
Few human endeavors are as beset by expensive failure as the quest to develop drugs – and new technologies rarely move the needle. Will generative AI be different? Hear the case for “yes.”
9:50 a.m.
Sponsor Session
How AI Can Help Us Make Better Medicines
10 min
Richard Bonneau, Ph.D., VP machine learning for drug discovery, Genentech
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
We’re in an unprecedented time where computational methods, especially from AI/Machine Learning, are becoming just as essential as biology and chemistry to the future of medicines. Genentech is pioneering a strategy called the “Lab in a Loop” – an iterative cycle of data, computation, experimentation, and discovery – that is accelerating and improving drug discovery and development.
10:00 a.m.
Going Deeper into Using Generative AI to Design Drugs
20 min
Colin Murdoch, president, Isomorphic Labs & chief business officer, Google DeepMind
Casey Ross, national health technology correspondent, STAT (moderator)
Few players have had a bigger impact when it comes to generative AI than DeepMind. Will that translate into drug development?
10:20 a.m.
Ranking Drug Companies on Innovation and Invention
5 min
Mike Rea, CEO, IDEA Pharma
IDEA Pharma unveils the 13th annual edition of its ranking of the companies that do the best jobs creating medicines and bringing them to market.
10:25 a.m.
COFFEE BREAK
30 min
10:55 a.m.
To Be Announced
30 min
11:25 a.m.
Sponsor Session
To Be Announced
10 min
11:35 p.m.
Science’s New Watchdogs
30 min
Elisabeth Bik, science integrity consultant
Sholto David, Ph.D., former analytical scientist
Jonathan Wosen, PhD., west coast biotech & life sciences reporter, STAT (moderator)
The discovery of reused or altered images in scientific papers is shining a bright and uncomfortable spotlight on the research world, leading to a string of retracted papers and even some surprising resignations. Meet two key figures in this major scientific moment for a tough discussion about what is coming next.
12:05 p.m.
LUNCH
90 min
1:35 p.m.
Demo: To Be Announced
1:45 p.m.
The STAT Startup Panel
30 min
Gilad Almogy, Ph.D., CEO and co-founder, Ultima Genomics
Dina Radenkovic, CEO, Gameto
Akira Matsuno, president, chief financial officer, and co-founder, Tune Therapeutics
Allison DeAngelis, biotech startups and venture capital reporter, STAT (moderator)
Come hear from four of the most interesting new companies in the health care universe – bridging drug development, health tech, and more. Find out the next targets for medical entrepreneurs.
2:15 p.m.
Sponsor Session
To Be Announced
10 min
2:25 p.m.
To Be Announced
20 min
2:45 p.m.
Can Wearables Still Upend Medicine?
30 min
Ida Sim, M.D., Ph.D., professor and chief research informatics officer, UCSF
Andy Coravos, managing director, HumanFirst, acquired by ICON
Mario Aguilar, health tech correspondent, STAT (moderator)
It’s been almost a decade since the Apple Watch started to catalyze a new interest in using wearables for medical diagnosis. But hype has met reality all too often. What is next, and what role should industry and academia play in changing how our devices monitor us?
3:15 p.m.
COFFEE BREAK
30 min
3:45 p.m.
A Biotech With Heart
25 min
Robert Blum, president & CEO, Cytokinetics
Adam Feuerstein, senior writer, biotech, STAT (moderator)
The story of Cytokinetics is one of perseverance, stubbornness, and setbacks overcome. Founded in 1997 to exploit emerging science in muscle biology, the company is finally on the cusp of its first drug approval for aficamten, a treatment for an inherited form of heart disease. Retrace the bumpy road to this triumphant moment and look toward the future with the company’s long-time CEO.
4:10 p.m.
Demo: To Be Announced
10 min
4:20 p.m.
To Be Announcced
30 min
4:50 p.m.
Setting Expectations for AI In Drug Development
35 min
Daphne Koller, CEO and founder, insitro
Derek Lowe, director, discovery sciences, Novartis; author, “In the Pipeline”
Vijay Pande, Ph.D., general partner, Andreessen Horowitz
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
Additional speakers to be announced
The advent of generative AI means hopes for advances in drug development have never been higher. What is realistic? What is not?
5:25 p.m.
Sponsor Session
Closing Remarks
5 min
Pierre Theodore, M.D., Head, Patient Impact and Health Equity, Genentech
5:30 p.m.
Closing from STAT
5 min
Open to all summit attendees.
5:35 p.m.
Networking Reception
90 min
Open to all summit attendees.
Location
Join us in San Francisco
The 2024 STAT Breakthrough Summit West will take place at the Commonwealth Club at 110 The Embarcadero, San Francisco, CA or tune in virtually with our cutting edge virtual event platform.
Attending in person? Reserve your room by April 15 to receive a discounted rate at the Harbor Court Hotel located next door to the venue.
New benefit
